Scholarlink

<p>This study aims to establish a technology for the dynamic monitoring and early identification of resistance to epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) in patients with non-small cell lung cancer (NSCLC). To achieve this, we first developed an osimertinib-resistant NSCLC cell model and employed a graphene oxide-based SELEX (GO-SELEX) strategy to screen for high-affinity single-stranded DNA aptamers. After multiple rounds of enrichment and validation, the selected Osi-1 aptamer exhibited optimal binding affinity to the supernatant of resistant cells. Subsequent pull-down immunoblotting analysis using Osi-1 identified calnexin as its specific target for the first time, with a dissociation constant (Kd) of 71.93 nM. Building on this, we developed a label-free gold nanoparticle (AuNP)-based aptamer sensing platform and systematically optimized key parameters, including NaCl concentration, aptamer dosage, and incubation time. The results demonstrated exceptional specificity in distinguishing drug-resistant from sensitive cells, exhibiting a highly linear response (R² = 0.9912) to calnexin concentrations ranging from 10 to 500 nM. The detection limit was&#xa0;7.89 nM, with excellent stability and recoveries (97.43%–107.12%) in serum samples. In summary, this study not only identifies calnexin as a potential biomarker for osimertinib resistance but also establishes a highly efficient, sensitive, and clinically translatable label-free detection platform, providing a novel solution for early monitoring and precision intervention in NSCLC drug resistance.</p> Graphical Abstract <p></p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Non-immobilized graphene oxide–based screening of aptamers for non-small cell lung cancer (NSCLC) drug resistance biomarkers and development of a nano-detection platform

  • 期刊论文

  • 发表日期：

    2026年1月7日

查看全文
  • Qiming Kou,
  • Lianju Chen,
  • Jie Qu,
  • Xu Wen,
  • Qijun Zuo,
  • Huimin Zhao,
  • Yuanning Luo,
  • Haoxiang Yan,
  • Fan Zhang,
  • Yanyan Wang,
  • Yulong Li,
  • Tianyu Feng,
  • Huiyan Wang,
  • Kexin Sun,
  • Gang Zhao

摘要

This study aims to establish a technology for the dynamic monitoring and early identification of resistance to epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) in patients with non-small cell lung cancer (NSCLC). To achieve this, we first developed an osimertinib-resistant NSCLC cell model and employed a graphene oxide-based SELEX (GO-SELEX) strategy to screen for high-affinity single-stranded DNA aptamers. After multiple rounds of enrichment and validation, the selected Osi-1 aptamer exhibited optimal binding affinity to the supernatant of resistant cells. Subsequent pull-down immunoblotting analysis using Osi-1 identified calnexin as its specific target for the first time, with a dissociation constant (Kd) of 71.93 nM. Building on this, we developed a label-free gold nanoparticle (AuNP)-based aptamer sensing platform and systematically optimized key parameters, including NaCl concentration, aptamer dosage, and incubation time. The results demonstrated exceptional specificity in distinguishing drug-resistant from sensitive cells, exhibiting a highly linear response (R² = 0.9912) to calnexin concentrations ranging from 10 to 500 nM. The detection limit was 7.89 nM, with excellent stability and recoveries (97.43%–107.12%) in serum samples. In summary, this study not only identifies calnexin as a potential biomarker for osimertinib resistance but also establishes a highly efficient, sensitive, and clinically translatable label-free detection platform, providing a novel solution for early monitoring and precision intervention in NSCLC drug resistance.

Graphical Abstract